MedTrace Logo

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

NCT02560116 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-01-21

No results posted yet for this study

Summary

The investigators aim to correlate noninvasive pulmonary artery systolic pressure (PASP) measurements obtained with and without echocardiographic contrast (Optison) during transthoracic echocardiography (TTE) with those obtained invasively and simultaneously during right heart catheterization, as the gold standard.

Conditions

  • Hypertension, Pulmonary

Sponsors & Collaborators

  • GE Healthcare

    collaborator INDUSTRY

  • Northwell Health

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02560116 on ClinicalTrials.gov